Home
overview
Hear from experienced professionals:
· Dr Gary Cupit, Vice President, Global Business Development & Licensing, Novartis
· Dr Lauren Silverman, Director, Licensing & Development, Pfizer
· Dr Ray Hill, Executive Director, Licensing & External Research, Europe, Merck
· Dr Adrian Carter, Senior Project Leader, Licensing & Contract Management, Boehringer Ingelheim
· Dr Wolfgang Schmidt, Scientific Affairs, Aventis
· Jürgen Heitmann, Head, Search & Evaluation, Novartis
· Dr Jonathan Turner, Head, Corporate Department, Business Development, Boehringer Ingelheim
· Onno Van de Stolpe, Chief Executive Officer, Galapagos Genomics
· Andrew Mackie, Head, Alliance Management, Antisoma
· Oliver Gandy, Legal Adviser, Pfizer

A comprehensive event where you will hear about:
· CHOOSING THE RIGHT PARTNER: Identify the key attributes
· LICENSING DEALS: Create better opportunities
· DEAL-MAKING: Evaluate the benefits of early and late stage deals
· UNDERSTANDING OF VALUE: Understanding through negotiation
· BEST PRACTICE APPROACH: Get to grips with the practicalities of joint ventures in the Pharma & Biotech industries
· THE COMMERCIAL ENVIRONMENT: Assess the influence of the market on collaborations

Conference programme

8:30 Registration and Coffee

9:00 Chairman's Opening Remarks

Dr Jim Phillips

Dr Jim Phillips, Chief Executive Officer, Bone Medical & Diabetology

9:10 TRENDS AFFECTING THE FUTURE OF DRUG DEVELOPMENT & COMMERCIALIZATION

Dr Gary Cupit

Dr Gary Cupit, Vice President, Global Business Development & Licensing, Novartis

  • Development of therapeutic agents for commercialisation has greater financial pressures
  • Emerging, fully integrated Biotechs are competing with Big Pharma for assets
  • Decreasing competitive life cycles, more complex FDA reviews, pricing and reimbursement concerns and the influence of consumer marketing have driven costs higher than anticipated
  • Assumptions in planning for sales, marketing and regulatory review must be challenged
  • Global markets are evolving at different rates influenced by economic as well as regulatory changes
  • 9:40 PARTNER PROCESS

    Dr Lauren Silverman

    Dr Lauren Silverman, Director, Licensing & Development, Pfizer

  • What are the risks associated with finding the right partner?
  • Companies positioning themselves as ‘partner of choice’
  • Identify key attributes in your partner
  • Align corporate culture
  • Strike a win-win agreement
  • Partnering strategies of the future
  • 10:20 BUILDING PARTNERSHIPS

    Andrew Mackie

    Andrew Mackie, Head, Alliance Management, Antisoma

  • The evolving and interdependence on Pharma
  • Partnering pitfalls and collaboration catastrophes
  • Adding mutual value through partnerships
  • Competition for partnering
  • early detection and prevention of conflicts
  • 11:00 Morning Coffee

    11:20 WHY COMPETITIVE INTELLIGENCE IS FUNDAMENTAL TO LICENSING DEALS & COLLABORATIVE ARRANGEMENTS

    Richard Withers

    Richard Withers, Managing Director, Europe, Fuld & Co.

  • What is CI and how is it commonly applied in the Life Sciences industry?
  • How CI can help spot opportunities – case study
  • How CI can help filter opportunities – case study
  • How CI can help negotiations with opportunities – case study
  • How CI can help new entities – case study
  • What does CI cost?
  • 12:00 INTEGRATED LICENSING

    Kevin Quinn

    Kevin Quinn, Manager, Business Planning & Information, Helsinn Healthcare

  • Integrated licensing: definition, role and partnership approaches
  • Case study: the successful integrated licensing of palonosetron to MGI Pharma for North America
  • Key issues for win-win partnerships with integrated licensing companies
  • 12:40 Networking Lunch

    14:00 EFFECTIVE LICENSING & COLLABORATIONS

    Dr Anne Bruinvels

    Dr Anne Bruinvels, Chief Executive Officer, Curidium

  • Building Biotech companies through strategic deal-making
  • Effective partnerships in research and development
  • The right partner: Pharma vs Biotech
  • Creating opportunities for successful licensing deals
  • R&D capabilities important to reinforcing development pipelines
  • Deal-making and making deals work
  • 14:40 MANAGING THE DEAL-MAKING PROCESS

    Dr Adrian Carter

    Dr Adrian Carter, Senior Project Leader, Licensing & Contract Management, Boehringer Ingelheim

  • Formulating strategy based on existing franchise
  • Locating the appropriate opportunity by screening and evaluation
  • Investigating product specifications and forecasting value
  • Negotiating for a common understanding of value
  • Integrating the deal to realise value
  • 15:20 Afternoon Tea

    15:40 CREATING A STRATEGY

    Jürgen Heitmann

    Jürgen Heitmann, Head, Search & Evaluation, Novartis

  • Why strategy is so important to successful licensing
  • Identifying strategic gaps and opportunities
  • Differentiating yourself as the partner of choice
  • Aligning licensing strategies with other line functions
  • Successful and efficient screening for strategic targets
  • 16:20 ALLIANCE MANAGEMENT ALONG THE VALUE CHAIN

    Dr Wolfgang Schmidt

    Dr Wolfgang Schmidt, Scientific Affairs, Aventis

  • Types of alliances
  • Tools and processes
  • Effective project management
  • Portfolio management and alignment to strategy
  • Biotech and relationship with partners
  • Build up and extension of scientific networks
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    8:30 Re-registration and Coffee

    9:00 Chairman's Opening Remarks

    Michael Stone

    Michael Stone, Of Counsel, Covington & Burling

    9:10 DEAL-MAKING AND FORWARD INTEGRATION

    Paul de Potocki

    Paul de Potocki, Senior Vice President, Commercial Operations, Biovitrum

  • Development of the Biotech business model
  • Alignment of company and partnership strategy
  • Partnering process and key deal parameters - the Biotech perspective
  • Achieving objectives for strategic development and forward integration
  • 9:40 TRENDS IN DEAL-MAKING

    Dr Ignacio Faus Santasusana

    Dr Ignacio Faus Santasusana, Director, Business Development & Licensing, Grupo Uriach

  • Partnerships through co-marketing rights
  • How are committees set up to manage partnering transactions?
  • Early stage in-licensing
  • Investment in technology
  • Value and importance of licensing
  • Assessing regulatory requirement due to development risk
  • 10:20 INTELLECTUAL PROPERTY DUE DILLIGENCE

    Dr David Harper

    Dr David Harper, Partner, McDonnell, Boehnen, Hulbert & Berghoff
    View Bio

  • Ownership
  • Licensed rights
  • Claim scope
  • Patentability and patent validity
  • Freedom to operate
  • Related issues
  • 11:00 Morning Coffee

    11:20 BEST APPROACH TO STRUCTURE LICENSING DEALS

    Michael Stone

    Michael Stone, Of Counsel, Covington & Burling

    Jürgen Heitmann

    Jürgen Heitmann, Head, Search & Evaluation, Novartis

    Dr Anne Bruinvels

    Dr Anne Bruinvels, Chief Executive Officer, Curidium

    Oliver Gandy

    Oliver Gandy, Legal Adviser, Pfizer

    12:00 STRATEGIC LICENSING AND ALLIANCE CAPABILITIES

    Dr Jonathan Turner

    Dr Jonathan Turner, Head, Corporate Department, Business Development, Boehringer Ingelheim

  • Adopting the best practice approach to portfolio
  • Management aiding the decision-making
  • Improvement of joint ventures
  • Sharing the workload
  • Stages of involvement for those approving deals
  • Deciding when to license and to obtain the best ROI
  • 12:40 Networking Lunch

    14:00 WHY ARE COMPANIES IN-LICENSING TECHNOLOGY INSTEAD OF ACQUIRING A TECHNOLOGY COMPANY?

    Dr Ray Hill

    Dr Ray Hill, Executive Director, Licensing & External Research, Europe, Merck

  • Are Big Pharma dependant on in-licensed products?
  • Companies building strong pipelines
  • Successful licensing deals matched with strategy
  • Assessing the risks: what is the chance of delivering the promise?
  • Key advantages and disadvantages
  • 14:40 CONTRACTUAL AND INTELLECTUAL PROPERTY ISSSUES

    Oliver Gandy

    Oliver Gandy, Legal Adviser, Pfizer

  • The fear of contamination – managing confidentiality
  • Dividing up new intellectual property
  • Royalties, milestones and reach throughs
  • Diligence obligations and the need for control
  • Warranty and indemnity issues
  • Termination and reversionary rights
  • 15:20 Afternoon Tea

    15:40 APPLICATION OF TAX EFFICIENT SUPPLY CHAIN MANAGEMENT FOR PHARMA & BIOTECH INDUSTRY

    Mehernosh Lentin

    Mehernosh Lentin, Director, OSM Consulting Partners (formerly Baxter)

  • The situation today
  • Industry drivers for Pharma and Biotech organisations
  • Evolution of a collaborative model - companies in-licensing technology instead of acquiring technology
  • Accessing technologies through alliances
  • Establishing a tax efficient model
  • Maximising corporate value while minimising financial risks and managing cash flows
  • 16:20 PLANNING FOR THE FUTURE

    Onno van de Stolpe

    Onno van de Stolpe, Chief Executive Officer, Galapagos Genomics

  • From idea to reality, from genomics platform to drug discovery
  • Identifying limitations to growth and success
  • Developing strategy for further growth and development
  • Structuring collaborative agreements
  • Optimising returns through complex deal terms
  • 17:00 Chairman's Closing Remarks and Close of Conference

    +

    Workshops

    Finding the <i>Right</i> Pharma Partner
    Workshop

    Finding the Right Pharma Partner

    The Hatton, at etc. venues
    28th April 2004
    London, United Kingdom

    Managing Pharmaceutical & Biotechnology Collaborations
    Workshop

    Managing Pharmaceutical & Biotechnology Collaborations

    The Hatton, at etc. venues
    28th April 2004
    London, United Kingdom

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.